Pharma Leader Series: Top 50 Ophthalmic Drug Manufacturers Market Report 2021-2031

Table of Content

---

1 Report Overview
1.1 Scope of Report
1.2 Reasons For Doing The Report
1.3 Why You Should Buy This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Primary Research
1.7.2 Secondary Research
1.8 Market Evaluation & Forecasting Methodology
1.9 COIVD-19 Impact Recovery Pattern Analysis
1.9.1 V-Shaped Recovery
1.9.2 U-Shaped Recovery
1.9.3 W-Shaped Recovery
1.9.4 L-Shaped Recovery
1.10 Frequently Asked Questions (FAQ)

2 Executive Summary
2.1 Global Incidence of Eye Disease Continues To Grow
2.2 High Unmet Clinical Need Remains To Develop Safer, More Efficacious Treatments With Patient-Friendly Formulations.
2.3 AMD is A Major Cause of Blindness in Older People
2.4 Glaucoma Affects More Than 60 Million People Worldwide
2.5 DES is Another Prevalent Age-Related Condition
2.6 Uveitis Affects Up To 50 Million People Worldwide And Is The Main Cause Of Sight Loss
2.7 The Recent Advances Driving The Field Forward, Patient Demographics And Market Trends
2.8 COVID-19 Impact on Ophthalmic Drug Manufacturers Market

3 Ophthalmic Drugs Market Overview
3.1 Retinal Diseases
3.2 Age-Related Macular Degeneration (AMD)
3.2.1 Disease Subtypes
3.2.2 Market Drivers for Dry AMD
3.2.3 Areas Of Unmet Clinical Need
3.2.4 New Therapies For Wet AMD
3.2.5 New Treatments For Dry AMD
3.2.6 New Therapies
3.2.7 Future Market Size
3.3 GLAUCOMA
3.3.1 Disease Subtypes
3.3.2 Diagnosis Rate
3.3.3 Current Treatment
3.3.4 Fixed Dose Combinations
3.3.5 Market Drivers
3.3.6 Areas Of Unmet Clinical Need
3.3.7 New Delivery Approaches And Formulations
3.3.8 New Therapies
3.4 Dry Eye Syndrome
3.4.1 Diagnosis Rate
3.4.2 Current Treatment
3.4.3 Market Drivers
3.4.4 Areas Of Unmet Clinical Need
3.4.5 New Therapies
3.4.6 New Formulations
3.4.7 Early-Stage Drug Development
3.5 UVEITIS
3.5.1 Diagnosis Rate
3.5.2 Current Treatment
3.5.3 Market Drivers
3.5.4 Areas Of Unmet Clinical Need
3.5.5 New Therapies
3.5.6 New Formulations
3.5.7 Early-Stage Drug Development

4 Market Dynamics
4.1 Factors Affecting Growth
4.1.1 How Product and Process Innovation Is Driving the Market?
4.1.2 Continuing Focus on Productivity, will It Boost the Sales?
4.1.3 Development Of New Drugs Carries More Risks
4.1.4 Why Stringent Regulations Are Important?
4.1.5 How Hard is It to Tackle Patent Expirations?
4.1.6 How Decreasing Research and Development Success Rates Affects the Market Growth?
4.2 Market Drivers
4.2.1 Why Ophthalmic Biosimilar Are Gaining Tractions in the Global Market?
4.2.2 Increased Focus on Orphan and Specialty Drugs Boosting Research and Sales
4.2.3 Generics: A Driver or Restraint?
4.2.4 Increasing Demand for Formulation Development Services
4.2.5 Ophthalmic Drug Manufacturers’ Move Toward Strategic Collaboration With Drug Delivery Technology Companies
4.3 Opportunities in the Global Market
4.3.1 Lack of Manufacturing and Packaging Capabilities
4.3.2 Pharma Companies Will Continue to Look For Ways To Cut Drug Costs
4.3.3 Need for New Drug Delivery Technologies
4.3.4 Chemical APIs Will Experience Resurgence after the Shift of Focus to Biological APIs
4.4 Growth Restrain
4.4.1 Backwards Integration for Generics Manufacturers
4.4.2 The US Generic Drug User Fee Act and API Manufacturing
4.4.3 Challenges in Contract Manufacturing
4.4.4 Challenges in Assessing the Market: Supply versus Demand
4.5 SWOT Analysis
4.6 Porter’s Five Forces Analysis
4.6.1 What is Porter Five (5) Forces
4.6.2 Threat of New Entrants (Low to Moderate)
4.6.3 Rivalry Among the Existing Players (High)
4.6.4 Bargaining Power of Suppliers (Low)
4.6.5 Threats from Substitute Products (Low to Moderate)
4.6.6 Bargaining Power of Buyers (High)

5 Global Ophthalmic Drug Manufacturer Market
5.1 Overview
5.1.1 Analysis of Market Status Before COVID-19
5.1.2 Analysis of Market V-Shaped Recovery Pattern
5.1.3 Analysis of Market W-Shaped Recovery Pattern
5.1.4 Analysis of Market U-Shaped Recovery Pattern
5.1.5 Analysis of Market L-Shaped Recovery Pattern
5.2 Regional Market Overview
5.2.1 Analysis of Market Status Before COVID-19
5.2.2 Analysis of Market V-Shaped Recovery Pattern
5.2.3 Analysis of Market W-Shaped Recovery Pattern
5.2.4 Analysis of Market U-Shaped Recovery Pattern
5.2.5 Analysis of Market L-Shaped Recovery Pattern

6 Competitive Landscape
6.1 Strategy and Tactics: The Importance of Outsourcing Wisely

7 Top 20 Big Ophthalmic Drugs Manufacturing Company Profiles
7.1 Why We Have Chosen These Companies
7.2 Johnson & Johnson Vision Company
7.2.1 Company Snapshot
7.2.2 Company Overview
7.2.3 Company Product Benchmarking
7.2.4 Company Financial Profile
7.2.5 Company Recent Developments
7.2.6 Company SWOT Analysis
7.2.7 Company Key Competitors in the Global Ophthalmic Market
7.2.8 Company Future Outlook
7.3 F. Hoffmann-La Roche AG Company
7.3.1 Company Snapshot
7.3.2 Company Overview
7.3.3 Company Product Benchmarking
7.3.4 Company Financial Profile
7.3.5 Company Recent Developments
7.3.6 Company SWOT Analysis
7.3.7 Company Key Competitors in the Global Ophthalmic Market
7.3.8 Company Future Outlook
7.4 Pfizer Pharmaceutical Company
7.4.1 Company Snapshot
7.4.2 Company Overview
7.4.3 Company Product Benchmarking
7.4.4 Company Financial Profile
7.4.5 Company Recent Developments
7.4.6 Company SWOT Analysis
7.4.7 Company Key Competitors in the Global Ophthalmic Market
7.4.8 Company Future Outlook
7.5 Novartis International AG Company
7.5.1 Company Snapshot
7.5.2 Company Overview
7.5.3 Company Product Benchmarking
7.5.4 Company Financial Profile
7.5.5 Company Recent Developments
7.5.6 Company SWOT Analysis
7.5.7 Company Key Competitors in the Global Ophthalmic Market
7.5.8 Company Future Outlook
7.6 Merck & Co. Pharmaceutical Company
7.6.1 Company Snapshot
7.6.2 Company Overview
7.6.3 Company Product Benchmarking
7.6.4 Company Financial Profile
7.6.5 Company Recent Developments
7.6.6 Company SWOT Analysis
7.6.7 Company Key Competitors in the Global Ophthalmic Market
7.6.8 Company Future Outlook
7.7 Allergan Pharmaceutical (Abbvie Inc) Company
7.7.1 Company Snapshot
7.7.2 Company Overview
7.7.3 Company Product Benchmarking
7.7.4 Company Financial Profile
7.7.5 Company Recent Developments
7.7.6 Company SWOT Analysis
7.7.7 Company Key Competitors in the Global Ophthalmic
7.7.8 Company Future Outlook
7.8 Takeda Pharmaceutical Company
7.8.1 Company Snapshot
7.8.2 Company Overview
7.8.3 Company Product Benchmarking
7.8.4 Company Financial Profile
7.8.5 Company Recent Developments
7.8.6 Company SWOT Analysis
7.8.7 Company Key Competitors in the Global Ophthalmic Market
7.8.8 Company Future Outlook
7.9 Essilor International S.A. Company
7.9.1 Company Snapshot
7.9.2 Company Overview
7.9.3 Company Product Benchmarking
7.9.4 Company Financial Profile
7.9.5 Company Recent Developments
7.9.6 Company SWOT Analysis
7.9.7 Company Key Competitors in the Global Ophthalmic Market
7.9.8 Company Future Outlook
7.10 Teva Pharmaceuticals Company
7.10.1 Company Snapshot
7.10.2 Company Overview
7.10.3 Company Product Benchmarking
7.10.4 Company Financial Profile
7.10.5 Company Recent Developments
7.10.6 Company SWOT Analysis
7.10.7 Company Key Competitors in the Global Ophthalmic Market
7.10.8 Company Future Outlook
7.11 Otsuka Pharmaceutical Company
7.11.1 Company Snapshot
7.11.2 Company Overview
7.11.3 Company Product Benchmarking
7.11.4 Company Financial Profile
7.11.5 Company Recent Developments
7.11.6 Company SWOT Analysis
7.11.7 Company Key Competitors in the Global Ophthalmic Market
7.11.8 Company Future Outlook
7.12 Bausch Health Company
7.12.1 Company Snapshot
7.12.2 Company Overview
7.12.3 Company Product Benchmarking
7.12.4 Company Financial Profile
7.12.5 Company Recent Developments
7.12.6 Company SWOT Analysis
7.12.7 Company Key Competitors in the Global Ophthalmic Market
7.12.8 Company Future Outlook
7.13 Alcon Inc Company
7.13.1 Company Snapshot
7.13.2 Company Overview
7.13.3 Company Product Benchmarking
7.13.4 Company Financial Profile
7.13.5 Company Recent Developments
7.13.6 Company SWOT Analysis
7.13.7 Company Key Competitors in the Global Ophthalmic Market
7.13.8 Company Future Outlook
7.14 Regeneron Pharmaceuticals Inc. Company
7.14.1 Company Snapshot
7.14.2 Company Overview
7.14.3 Company Product Benchmarking
7.14.4 Company Financial Profile
7.14.5 Company Recent Developments
7.14.6 Company SWOT Analysis
7.14.7 Company Key Competitors in the Global Ophthalmic Market
7.14.8 Company Future Outlook
7.15 Recipharm publ AB Company
7.15.1 Company Snapshot
7.15.2 Company Overview
7.15.3 Company Product Benchmarking
7.15.4 Company Financial Profile
7.15.5 Company Recent Developments
7.15.6 Company SWOT Analysis
7.15.7 Company Key Competitors in the Global CMO Market
7.15.8 Company Future Outlook
7.16 Beximco Pharmaceuticals Limited Company
7.16.1 Company Snapshot
7.16.2 Company Overview
7.16.3 Company Financial Profile
7.16.4 Company Product Benchmarking
7.16.5 Company Recent Developments
7.16.6 Company SWOT Analysis
7.16.7 Company Key Competitors in the Global Ophthalmic Market
7.17 Edwards Lifesciences Company
7.17.1 Company Snapshot
7.17.2 Company Overview
7.17.3 Company Product Benchmarking
7.17.4 Company Financial Profile
7.17.5 Company Recent Developments
7.17.6 Company SWOT Analysis
7.17.7 Company Key Competitors in the Global Ophthalmic Market
7.17.8 Company Future Outlook
7.18 Cooper vision Company
7.18.1 Company Snapshot
7.18.2 Company Overview
7.18.3 Company Product Benchmarking
7.18.4 Company Financial Profile
7.18.5 Company Recent Developments
7.18.6 Company SWOT Analysis
7.18.7 Company Key Competitors in the Global Ophthalmic Market
7.19 Santen Pharmaceuticals Company
7.19.1 Company Snapshot
7.19.2 Company Overview
7.19.3 Company Product Benchmarking
7.19.4 Company Financial Profile
7.19.5 Company Recent Developments
7.19.6 Company SWOT Analysis
7.19.7 Company Key Competitors in the Global Ophthalmic Market
7.20 Rohto Pharmaceutical Company
7.20.1 Company Snapshot
7.20.2 Company Overview
7.20.3 Company Product Benchmarking
7.20.4 Company Financial Profile
7.20.5 Company Recent Developments
7.20.6 Company SWOT Analysis
7.20.7 Company Key Competitors in the Global Ophthalmic Market
7.21 Carl zeiss meditech AG Company
7.21.1 Company Snapshot
7.21.2 Company Overview
7.21.3 Company Product Benchmarking
7.21.4 Company Financial Profile
7.21.5 Company Recent Developments
7.21.6 Company SWOT Analysis
7.21.7 Company Key Competitors in the Global Ophthalmic Market
7.21.8 Company Future Outlook

8 Top 20 Mid-Range Ophthalmic Drugs Manufacturing Company Profiles
8.1 Why We Have Chosen These Companies?
8.2 Topcon Corporation Company
8.2.1 Company Snapshot
8.2.2 Company Overview
8.2.3 Company Product Benchmarking
8.2.4 Company Financial Profile
8.2.5 Company Recent Developments
8.2.6 Company SWOT Analysis
8.2.7 Company Key Competitors in the Global Ophthalmic Market
8.2.8 Company Future Outlook
8.3 Veeva System Inc Company
8.3.1 Company Snapshot
8.3.2 Company Overview
8.3.3 Company Product Benchmarking
8.3.4 Company Financial Profile
8.3.5 Company Recent Developments
8.3.6 Company SWOT Analysis
8.3.7 Company Key Competitors in the Global Ophthalmic Market
8.3.8 Company Future Outlook
8.4 Menicon co ltd. Company
8.4.1 Company Snapshot
8.4.2 Company Overview
8.4.3 Company Product Benchmarking
8.4.4 Company Financial Profile
8.4.5 Company Recent Developments
8.4.6 Company SWOT Analysis
8.4.7 Company Key Competitors in the Global Ophthalmic Market
8.4.8 Company Future Outlook
8.5 Chengdu Kanghong Pharmaceuticals Company
8.5.1 Company Snapshot
8.5.2 Company Overview
8.5.3 Company Product Benchmarking
8.5.4 Company Financial Profile
8.5.5 Company Recent Developments
8.5.6 Company SWOT Analysis
8.5.7 Company Key Competitors in the Global Ophthalmic Market
8.6 Nidek Co. Ltd Company
8.6.1 Company Snapshot
8.6.2 Company Overview
8.6.3 Company Product Benchmarking
8.6.4 Company Recent Developments
8.6.5 Company SWOT Analysis
8.6.6 Company Key Competitors in the Global Ophthalmic Market
8.6.7 Company Future Outlook
8.7 Glaukos Corporation Company
8.7.1 Company Snapshot
8.7.2 Company Overview
8.7.3 Company Product Benchmarking
8.7.4 Company Financial Profile
8.7.5 Company Recent Developments
8.7.6 Company SWOT Analysis
8.7.7 Company Key Competitors in the Global Ophthalmic Market
8.7.8 Company Future Outlook
8.8 Staar Surgical Company
8.8.1 Company Snapshot
8.8.2 Company Overview
8.8.3 Company Product Benchmarking
8.8.4 Company Financial Profile
8.8.5 Company Recent Developments
8.8.6 Company SWOT Analysis
8.8.7 Company Key Competitors in the Global Ophthalmic Market
8.9 Omeros Corporation Company
8.9.1 Company Snapshot
8.9.2 Company Overview
8.9.3 Company Product Benchmarking
8.9.4 Company Financial Profile
8.9.5 Company Recent Developments
8.9.6 Company SWOT Analysis
8.9.7 Company Key Competitors in the Global Ophthalmic Market
8.10 Aeries pharmaceuticals Company
8.10.1 Company Snapshot
8.10.2 Company Overview
8.10.3 Company Product Benchmarking
8.10.4 Company Financial Profile
8.10.5 Company Recent Developments
8.10.6 Company SWOT Analysis
8.10.7 Company Key Competitors in the Global Ophthalmic Market
8.11 Hoya Corporation Company
8.11.1 Company Snapshot
8.11.2 Company Overview
8.11.3 Company Product Benchmarking
8.11.4 Company Financial Profile
8.11.5 Company SWOT Analysis
8.11.6 Company Key Competitors in the Global Ophthalmic Market
8.11.7 Company Future Outlook
8.12 HORAMA Company
8.12.1 Company Snapshot
8.12.2 Company Overview
8.12.3 Company Product Benchmarking
8.12.4 Company Recent Developments
8.12.5 Company SWOT Analysis
8.12.6 Company Key Competitors in the Global Ophthalmic Market
8.12.7 Company Future Outlook
8.13 Alimera science Company
8.13.1 Company Snapshot
8.13.2 Company Overview
8.12.3 Company Product Benchmarking
8.12.4 Company Financial Profile
8.13.5 Company Recent Developments
8.13.6 Company SWOT Analysis
8.13.7 Company Key Competitors in the Global Ophthalmic Market
8.13.8 Company Future Outlook
8.14 Bora Pharmaceuticals Company
8.14.1 Company Snapshot
8.14.2 Company Overview
8.14.3 Company Product Benchmarking
8.14.4 Company Financial Profile
8.14.5 Company Recent Developments
8.14.6 Company SWOT Analysis
8.14.7 Company Key Competitors in the Global Ophthalmic Market
8.14.8 Company Future Outlook
8.15 Iridex Corporation Company
8.15.1 Company Snapshot
8.15.2 Company Overview
8.15.3 Company Product Benchmarking
8.15.4 Company Financial Profile
8.15.5 Company Recent Developments
8.15.6 Company SWOT Analysis
8.15.7 Company Key Competitors in the Global Ophthalmic Market
8.15.8 Company Future Outlook
8.16 Eyepoint Pharmaceutical Company
8.16.1 Company Snapshot
8.16.2 Company Overview
8.16.3 Company Product Benchmarking
8.16.4 Company Financial Profile
8.16.5 Company Recent Developments
8.16.6 Company SWOT Analysis
8.16.7 Company Key Competitors in the Global Ophthalmic Market
8.17 Kalvista Pharmaceuticals Inc Company
8.17.1 Company Snapshot
8.17.2 Company Overview
8.17.3 Company Product Benchmarking
8.17.4 Company Financial Profile
8.17.5 Company SWOT Analysis
8.17.6 Company Key Competitors in the Global Ophthalmic Market
8.17.7 Company Future Outlook
8.18 Ellex Medical Lasers Ltd. Company (Nova Eye Medical)
8.18.1 Company Snapshot
8.18.2 Company Overview
8.18.3 Company Product Benchmarking
8.18.4 Company Financial Profile
8.18.5 Company SWOT Analysis
8.18.6 Company Key Competitors in the Global Ophthalmic Market
8.18.7 Company Future Outlook
8.19 Oxurion NV Company (ThromboGenics)
8.19.1 Company Snapshot
8.19.2 Company Overview
8.19.3 Company Product Benchmarking
8.19.4 Company Financial Profile
8.19.5 Company SWOT Analysis
8.19.6 Company Key Competitors in the Global Ophthalmic Market
8.19.7 Company Future Outlook
8.20 EyeGate Pharmaceuticals Company
8.20.1 Company Snapshot
8.20.2 Company Overview
8.20.3 Company Product Benchmarking
8.20.4 Company Financial Profile
8.20.5 Company Recent Developments
8.20.6 Company SWOT Analysis
8.20.7 Company Key Competitors in the Global Ophthalmic Market
8.20.8 Company Future Outlook
8.21 Ophthalix, Inc (Wize Pharma Inc) Company
8.21.1 Company Snapshot
8.21.2 Company Overview
8.21.3 Company Product Benchmarking
8.21.4 Company Financial Profile
8.21.5 Company Recent Developments
8.21.6 Company SWOT Analysis
8.21.7 Company Key Competitors in the Global Ophthalmic Market

9 Top 10 Ophthalmic Drugs Manufacturing Companies to Watch
9.1 Why We Have Chosen These Companies?
9.2 GenSight Biologics Company
9.2.1 Company Snapshot
9.2.2 Company Overview
9.2.3 Company Product Benchmarking
9.2.4 Company Financial Profile
9.2.5 Company Recent Developments
9.2.6 Company SWOT Analysis
9.2.7 Company Key Competitors in the Global Ophthalmic Market
9.3 Neurotech Pharmaceuticals Inc Company
9.3.1 Company Snapshot
9.3.2 Company Overview
9.3.3 Company Product Benchmarking
9.3.4 Company SWOT Analysis
9.3.5 Company Key Competitors in the Global Ophthalmic Market
9.4 Phio Pharmaceuticals Company
9.4.1 Company Snapshot
9.4.2 Company Overview
9.4.3 Company Product Benchmarking
9.4.4 Company Financial Profile
9.4.5 Company Recent Developments
9.4.6 Company SWOT Analysis
9.4.7 Company Key Competitors in the Global Ophthalmic Market
9.4.8 Company Future Outlook
9.5 Kubota Pharmaceutical Holdings Co Ltd Company
9.5.1 Company Snapshot
9.5.2 Company Overview
9.5.3 Company Product Benchmarking
9.5.4 Company Financial Profile
9.5.5 Company Recent Developments
9.5.6 Company SWOT Analysis
9.5.7 Company Key Competitors in the Global Ophthalmic Market
9.6 Aerpio Therapeutics Company
9.6.1 Company Snapshot
9.6.2 Company Overview
9.6.3 Company Product Benchmarking
9.6.4 Company Financial Profile
9.6.5 Company Recent Developments
9.6.6 Company SWOT Analysis
9.6.7 Company Key Competitors in the Global Ophthalmic Market
9.6.8 Company Future Outlook
9.7 Ampio Pharmaceuticlas Company
9.7.1 Company Snapshot
9.7.2 Company Overview
9.7.3 Company Product Benchmarking
9.7.4 Company Financial Profile
9.7.5 Company Recent Developments
9.7.6 Company SWOT Analysis
9.7.7 Company Key Competitors in the Global Ophthalmic Market
9.8 Kodiak Sciences Company
9.8.1 Company Snapshot
9.8.2 Company Overview
9.8.3 Company Product Benchmarking
9.8.4 Company Financial Profile
9.8.5 Company Recent Developments
9.8.6 Company SWOT Analysis
9.8.7 Company Key Competitors in the Global Ophthalmic Market
9.8.8 Company Future Outlook
9.9 Opsis Therapeutics Company
9.9.1 Company Snapshot
9.9.2 Company Overview
9.9.3 Company Product Benchmarking
9.9.4 Company SWOT Analysis
9.9.5 Company Key Competitors in the Global Ophthalmic Market
9.10 Grevis Pharmaceuticals Company
9.10.1 Company Snapshot
9.10.2 Company Overview
9.10.3 Company Product Benchmarking
9.10.4 Company SWOT Analysis
9.10.5 Company Key Competitors in the Global Ophthalmic Market
9.10.6 Company Future Outlook
9.11 Innovexia Lifesciences Company
9.11.1 Company Snapshot
9.11.2 Company Overview
9.11.3 Company Product Benchmarking
9.11.4 Company SWOT Analysis
9.11.5 Company Key Competitors in the Global Ophthalmic Market
9.11.6 Company Future Outlook

10 Conclusion and Recommendations
10.1 Recommendations

11 Glossary

List of Tables

---

Table 1. Global Ophthalmic Drug Manufacturer Market Summary Table
Table 2. Products Approved To Treat Wet AMD
Table 3. Global AMD Sales Of Approved Products By Company, Through 2019 ($ Millions)
Table 4. Global Market Share Of AMD Approved Products By Company, 2019
Table 5. Areas Of Unmet Clinical Need In Amd Treatment
Table 6. Products In Development For Wet AMD – Phase Iii
Table 7. Products In Development For Wet AMD - Phase II
Table 8. Products In Development For Wet AMD - Phase I
Table 9. Products In Development For Dry AMD - Phase III
Table 10. Products In Development For Dry AMD - Phase II
Table 11. Global AMD Sales Of Pipeline Products, 2019 ($ Millions)
Table 12. Approved Glaucoma Drug Characteristics
Table 13. Products Approved To Treat Glaucoma – Monotherapy
Table 14. Products Approved To Treat Glaucoma - Fixed Dose Combinations
Table 15. Prescription Drug Classes In The U.S., 2019
Table 16. Prescription Drug Classes In Europe, 2019
Table 17. Prescription Drug Classes In Japan, 2019
Table 18. Global Glaucoma Sales Of Approved Products, Through 2020 ($ Millions)
Table 19. Global Glaucoma Sales Of Approved Products By Drug Class, Through 2019 ($ Millions)
Table 20. Global Market Share Of Glaucoma Approved Products By Drug Class
Table 21. Global Glaucoma Sales Of Approved Products By Company, Through 2019 ($ Millions)
Table 22. Global Market Share Of Glaucoma Approved Products By Company, 2014
Table 23. Areas Of Unmet Clinical Need In Glaucoma Treatment
Table 24. Products In Development To Treat Glaucoma - Phase III
Table 25. Products In Development To Treat Glaucoma - Phase II
Table 26. Products In Development To Treat Glaucoma - Phase I
Table 27. Rock Inhibitors In Development
Table 28. Gene Silencing Agents In Development
Table 29. Global Glaucoma Sales Of Pipeline Products, Through 2020 ($ Millions)
Table 30. Products Approved To Treat DES
Table 31. Global DES Sales Of Approved Products, 2020 ($ Millions)
Table 32. Global Des Sales Of Approved Products By Drug Class, 2020 ($ Millions)
Table 33. GLOBAL MARKET SHARE OF DES APPROVED PRODUCTS BY DRUG CLASS, 2020 (%)
Table 34. Global DES Sales Of Approved Products By Company, 2020 ($ Millions)
Table 35. Global Market Share Of Des Approved Products By Company, 2020, (%)
Table 36. Areas Of Unmet Clinical Need In Des Treatment
Table 37. Products In Development To Treat Des - Phase III
Table 38. Products In Development To Treat Des - Phase II
Table 39. Global Des Sales Of Pipeline Products, 2020 ($ Millions)
Table 40. Products Approved To Treat UVEITIS
Table 41. Global UVEITIS Sales Of Approved Products, 2020, ($ Millions)
Table 42. Global UVEITIS Sales Of Approved Products By Company, 2020, ($ Millions)
Table 43. Global Market Share Of UVEITIS Approved Products By Company, 2020
Table 44. Areas Of Unmet Clinical Need In Uveitis Treatment
Table 45. Products In Development To Treat UVEITIS - Phase III
Table 46. Products In Development To Treat UVEITIS - Phase Ii
Table 47. Products In Development To Treat UVEITIS - Phase I
Table 48. Global Uveitis Sales Of Pipeline Products, 2020 ($ Millions)
Table 49. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 50. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 51. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 52. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 53. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 54. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 55. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 56. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 57. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 58. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 59. Johnson & Johnson Vision: Company Information
Table 60. Johnson & Johnson Vision: Company Product and Service Offerings
Table 61. Johnson & Johnson Vision: Company Product Pipeline
Table 62. Johnson & Johnson Vision: Company Financial Strengths Analysis 2019 (US$ Million)
Table 63. Johnson & Johnson Vision: Company Growth Share Analysis 2019 (%)
Table 64. Johnson & Johnson Vision: Company Recent Developments till Jan, 2021
Table 65. Johnson & Johnson Vision: Company Recent Developments till Jan, 2021
Table 66. F. Hoffmann-La Roche AG: Company Information
Table 67. F. Hoffmann-La Roche AG: Company Product and Service Offerings
Table 68. F. Hoffmann-La Roche AG: Company Product Pipeline
Table 69. F. Hoffmann-La Roche AG: Company Financial Strengths Analysis 2019 (US$ Million)
Table 70. F. Hoffmann-La Roche AG : Company Growth Share Analysis 2019 (%)
Table 71. F. Hoffmann-La Roche AG: Company Recent Developments till Jan, 2021
Table 72. F. Hoffmann-La Roche AG: Company Recent Developments till Jan, 2021
Table 73. Pfizer Pharmaceutical: Company Information
Table 74. Pfizer Pharmaceutical: Company Product and Service Offerings
Table 75. Pfizer Pharmaceuticals: Company Product Pipeline
Table 76. Pfizer Pharmaceutical: Company Financial Strengths Analysis 2019 (US$ Million)
Table 77. Pfizer Pharmaceutical: Company Growth Share Analysis 2019 (%)
Table 78. Pfizer Pharmaceutical: Company Recent Developments till Jan, 2021
Table 79. Pfizer Pharmaceutical: Company Recent Developments till Jan, 2021
Table 80. Novartis AG: Company Information
Table 81. Novartis AG: Company Product and Service Offerings
Table 82. Novartis AG: Company Product Pipeline
Table 83. Novartis AG: Company Financial Strengths Analysis 2019 (US$ Million)
Table 84. Novartis AG: Company Growth Share Analysis 2019 (%)
Table 85. Novartis AG: Company Recent Developments till Jan, 2021
Table 86. Novartis AG: Company Recent Developments till Jan, 2021
Table 87. Merck & Co., Inc: Company Information
Table 88. Merck & Co., Inc: Company Product and Service Offerings
Table 89. Merck & Co. Inc: Company Product Pipeline
Table 90. Merck & Co., Inc: Company Financial Strengths Analysis 2019 (US$ Million)
Table 91. Merck & Co., Inc: Company Growth Share Analysis 2019 (%)
Table 92. Merck & Co., Inc: Company Recent Developments till Jan, 2021
Table 93. Merck & Co., Inc: Company Recent Developments till Jan, 2021
Table 94. AbbVie Inc.: Company Information
Table 95. AbbVie Inc.: Company Product and Service Offerings
Table 96. Abbvie Inc: Company Product Pipeline
Table 97. AbbVie Inc.: Company Financial Strengths Analysis 2019 (US$ Million)
Table 98. AbbVie Inc.: Company Growth Share Analysis 2019 (%)
Table 99. AbbVie Inc.: Company Recent Developments till Jan, 2021
Table 100. AbbVie Inc.: Company Recent Developments till Jan, 2021
Table 101. Takeda Pharmaceutical: Company Information
Table 102. Takeda Pharmaceutical: Company Product and Service Offerings
Table 103. Takeda Pharmaceuticals: Company Product Pipeline
Table 104. Takeda Pharmaceutical : Company Financial Strengths Analysis 2019 (US$ Million)
Table 105. Takeda Pharmaceutical : Company Growth Share Analysis 2019 (%)
Table 106. Takeda Pharmaceuticals: Company Recent Developments till December,2020
Table 107. Takeda Pharmaceuticals: Company Recent Developments till December,2020
Table 108. Essilor International Company: Company Information
Table 109. Essilor International Company: Company Product and Service Offerings
Table 110. Essilor International Company: Company Financial Strengths Analysis 2019 (US$ Million)
Table 111. Essilor International Company: Company Growth Share Analysis 2019 (%)
Table 112. Essilor International Company: Company Recent Developments till Jan, 2021
Table 113. Essilor International Company: Company Recent Developments till Jan, 2021
Table 114. Teva Pharmaceutical: Company Information
Table 115. Teva Pharmaceutical: Company Product and Service Offerings
Table 116. Teva Pharmaceutical: Company Financial Strengths Analysis 2019 (US$ Million)
Table 117. Teva Pharmaceutical: Company Growth Share Analysis 2019 (%)
Table 118. Teva Pharmaceutical: Company Recent Developments till Jan, 2021
Table 119. Teva Pharmaceutical: Company Recent Developments till Jan, 2021
Table 120. Otsuka Holdings Co., Ltd: Company Information
Table 121. Otsuka Holdings Co., Ltd: Company Product and Service Offerings
Table 122. Otsuka Pharmaceuticals: Company Product Pipeline
Table 123. Otsuka Holdings Co., Ltd: Company Financial Strengths Analysis 2019 (US$ Million)
Table 124. Otsuka Holdings Co., Ltd: Company Growth Share Analysis 2019 (%)
Table 125. Otsuka Holdings Co., Ltd: Company Recent Developments till Jan, 2021
Table 126. Otsuka Holdings Co., Ltd: Company Recent Developments till Jan, 2021
Table 127. Bausch Health Companies Inc: Company Information
Table 128. Bausch Health Companies Inc: Company Product and Service Offerings
Table 129. Bausch Health Companies Inc: Company Product Pipeline
Table 130. Bausch Health Companies Inc: Company Financial Strengths Analysis 2019 (US$ Million)
Table 131. Bausch Health Companies Inc: Company Growth Share Analysis 2019 (%)
Table 132. Bausch Health Companies Inc: Company Recent Developments till Jan, 2021
Table 133. Bausch Health Companies Inc: Company Recent Developments till Jan, 2021
Table 134. Alcon Inc: Company Information
Table 135. Alcon Inc: Company Product and Service Offerings
Table 136. Alcon Inc: Company Financial Strengths Analysis 2019 (US$ Million)
Table 137. Alcon Inc: Company Growth Share Analysis 2019 (%)
Table 138. Alcon Inc: Company Recent Developments till Jan, 2021
Table 139. Alcon Inc: Company Recent Developments till Jan, 2021
Table 140. Regeneron Pharmaceuticals, Inc: Company Information
Table 141. Regeneron Pharmaceuticals, Inc: Company Product and Service Benchmarking
Table 142. Regeneron Pharmaceuticals, Inc: Company Product Pipeline
Table 143. Regeneron Pharmaceuticals, Inc: Company Financial Strengths Analysis 2019 (US$ Million)
Table 144. Regeneron Pharmaceuticals, Inc: Company Growth Share Analysis 2019 (%)
Table 145. Regeneron Pharmaceuticals, Inc: Company Recent Developments till December,2020
Table 146. Regeneron Pharmaceuticals, Inc: Company Recent Developments till December,2020
Table 147. Recipharm publ AB: Company Information
Table 148. Recipharm publ AB: Company Product and Service Benchmarking
Table 149. Recipharm publ AB: Company Financial Strengths Analysis 2019 (US$ Million)
Table 150. Recipharm publ AB: Company Growth Share Analysis 2019 (%)
Table 151. Recipharm publ AB: Company Recent Developments till December,2020
Table 152. Recipharm publ AB: Company Recent Developments till December,2020
Table 153. Beximco Pharmaceuticals Limited: Company Information
Table 154. Beximco Pharmaceuticals Limited: Company Financial Strengths Analysis 2019 (US$ Million)
Table 155. Beximco Pharmaceuticals Limited: Company Growth Share Analysis 2019 (%)
Table 156. Beximco Pharmaceuticals Limited: Company Product and Service Benchmarking
Table 157. Beximco Pharmaceuticals Limited: Company Recent Developments till December,2020
Table 158. Beximco Pharmaceuticals Limited: Company Recent Developments till December,2020
Table 159. Edwards Lifesciences: Company Information
Table 160. Edwards Lifesciences: Company Product and Service Offerings
Table 161. Edwards Lifesciences: Company Financial Strengths Analysis 2019 (US$ Million)
Table 162. Edwards Lifesciences: Company Growth Share Analysis 2019 (%)
Table 163. Edwards Lifesciences: Company Recent Developments till Jan, 2021
Table 164. Edwards Lifesciences: Company Recent Developments till Jan, 2021
Table 165. Cooper Companies, Inc.: Company Information
Table 166. Cooper Companies, Inc.: Company Product and Service Offerings
Table 167. Cooper Companies, Inc.: Company Financial Strengths Analysis 2019 (US$ Million)
Table 168. Cooper Companies, Inc.: Company Growth Share Analysis 2019 (%)
Table 169. Cooper Companies, Inc.: Company Recent Developments till Jan, 2021
Table 170. Cooper Companies, Inc.: Company Recent Developments till Jan, 2021
Table 171. Santen Pharmaceutical Co., Ltd: Company Information
Table 172. Santen Pharmaceutical Co., Ltd: Company Product and Service Offerings
Table 173. Santen Pharmaceutical Co., Ltd: Company Financial Strengths Analysis 2019 (US$ Million)
Table 174. Santen Pharmaceutical Co., Ltd: Company Growth Share Analysis 2019 (%)
Table 175. Santen Pharmaceutical Co., Ltd: Company Recent Developments till Jan, 2021
Table 176. Santen Pharmaceutical Co., Ltd: Company Recent Developments till Jan, 2021
Table 177. Rohto Pharmaceutical: Company Information
Table 178. Rohto Pharmaceutical : Company Product and Service Offerings
Table 179. Rohto Pharmaceutical: Company Financial Strengths Analysis 2019 (US$ Million)
Table 180. Rohto Pharmaceutical : Company Growth Share Analysis 2019 (%)
Table 182. Rohto Pharmaceutical: Company Recent Developments till Jan, 2021
Table 183. Carl Zeiss Meditec AG: Company Information
Table 184. Carl Zeiss Meditech AG: Company Product and Service Offerings
Table 185. Carl Zeiss Meditec AG: Company Financial Strengths Analysis 2019 (US$ Million)
Table 186. Carl Zeiss Meditec AG: Company Growth Share Analysis 2019 (%)
Table 187. Carl Zeiss Meditec AG: Company Recent Developments till Jan, 2021
Table 188. Carl Zeiss Meditec AG: Company Recent Developments till Jan, 2021
Table 189. Topcon Corporation: Company Information
Table 190. Topcon Corporation: Company Product and Service Offerings
Table 191. Topcon Corporation: Company Financial Strengths Analysis 2019 (US$ Million)
Table 192. Topcon Corporation: Company Growth Share Analysis 2019 (%)
Table 193. Topcon Corporation: Company Recent Developments till Jan, 2021
Table 194. Topcon Corporation: Company Recent Developments till Jan, 2021
Table 195. Veeva Systems Inc: Company Information
Table 196. Veeva Systems Inc: Company Product and Service Offerings
Table 197. Veeva Systems Inc: Company Financial Strengths Analysis 2019 (US$ Million)
Table 198. Veeva Systems Inc: Company Growth Share Analysis 2019 (%)
Table 199. Veeva Systems Inc: Company Recent Developments till Jan, 2021
Table 200. Veeva Systems Inc: Company Recent Developments till Jan, 2021
Table 201. Menicon Co., Ltd: Company Information
Table 202. Menicon Co., Ltd: Company Product and Service Offerings
Table 203. Menicon Co., Ltd: Company Financial Strengths Analysis 2019 (US$ Million)
Table 204. Menicon Co., Ltd: Company Growth Share Analysis 2019 (%)
Table 205. Menicon Co., Ltd: Company Recent Developments till Jan, 2021
Table 206. Menicon Co., Ltd: Company Recent Developments till Jan, 2021
Table 207. Chengdu Kanghong Pharmaceutical Group Co., Ltd: Company Information
Table 208. Chengdu Kanghong Pharmaceutical Group Co., Ltd: Company Product and Service Offerings
Table 209. Chengdu Kanghong Pharmaceutical Group Co., Ltd: Company Financial Strengths Analysis 2019 (US$ Million)
Table 210. Chengdu Kanghong Pharmaceutical Group Co., Ltd: Company Growth Share Analysis 2019 (%)
Table 211. Chengdu Kanghong Pharmaceutical Group Co., Ltd: Company Growth Share Analysis 2019 (%)
Table 212. Nidek Co. Ltd: Company Information
Table 213. Nidek Co. Ltd: Company Product and Service Offerings
Table 214. Nidek Co. Ltd: Company Recent Developments till Jan, 2021
Table 215. Nidek Co. Ltd: Company Recent Developments till Jan, 2021
Table 216. Glaukos Corporation: Company Information
Table 217. Glaukos Corporation: Company Product and Service Offerings
Table 218. Glaukos Corporation: Company Financial Strengths Analysis 2019 (US$ Million)
Table 219. Glaukos Corporation: Company Growth Share Analysis 2019 (%)
Table 220. Glaukos Corporation: Company Recent Developments till Jan, 2021
Table 221. Glaukos Corporation: Company Recent Developments till Jan, 2021
Table 222. STAAR Surgical: Company Information
Table 223. STAAR Surgical: Company Product and Service Offerings
Table 224. STAAR Surgical: Company Financial Strengths Analysis 2019 (US$ Million)
Table 225. STAAR Surgical: Company Growth Share Analysis 2019 (%)
Table 226. STAAR Surgical: Company Recent Developments till Jan, 2021
Table 227. STAAR Surgical: Company Recent Developments till Jan, 2021
Table 228. Omeros Corporation: Company Information
Table 229. Omeros Corporation: Company Product and Service Offerings
Table 230. Omeros Corporation: Company Financial Strengths Analysis 2019 (US$ Million)
Table 231. Omeros Corporation: Company Growth Share Analysis 2019 (%)
Table 232. Omeros Corporation: Company Recent Developments till Jan, 2021
Table 233. Omeros Corporation: Company Recent Developments till Jan, 2021
Table 234. Aerie Pharmaceuticals, Inc: Company Information
Table 235. Aerie Pharmaceuticals, Inc: Company Product and Service Offerings
Table 236. Aerie Pharmaceuticals, Inc: Company Financial Strengths Analysis 2019 (US$ Million)
Table 237. Aerie Pharmaceuticals, Inc: Company Growth Share Analysis 2019 (%)
Table 238. Aerie Pharmaceuticals, Inc: Company Recent Developments till Jan, 2021
Table 239. Aerie Pharmaceuticals, Inc: Company Recent Developments till Jan, 2021
Table 240. Hoya Corporation: Company Information
Table 241. Hoya Corporation: Company Product and Service Offerings
Table 242. Hoya Corporation: Company Financial Strengths Analysis 2019 (US$ Million)
Table 243. Hoya Corporation: Company Growth Share Analysis 2019 (%)
Table 244. Hoya Corporation: Company Growth Share Analysis 2019 (%)
Table 245. Opsis Therapeutics: Company Information
Table 246. Opsis Therapeutics: Company Product and Service Offerings
Table 247. HORAMA Pharmaceuticals: Company Product Pipeline
Table 248. Opsis Therapeutics: Company Recent Developments till Jan, 2021
Table 249. Opsis Therapeutics: Company Recent Developments till Jan, 2021
Table 250. Alimera Sciences, Inc.: Company Information
Table 251. Alimera Sciences, Inc.: Company Product and Service Offerings
Table 252. Alimera Sciences, Inc.: Company Financial Strengths Analysis 2019 (US$ Million)
Table 253. Alimera Sciences, Inc.: Company Growth Share Analysis 2019 (%)
Table 254. Alimera Sciences, Inc.: Company Recent Developments till Jan, 2021
Table 255. Alimera Sciences, Inc.: Company Recent Developments till Jan, 2021
Table 256. Bora Pharmaceuticals Co., Ltd: Company Information
Table 257. Bora Pharmaceuticals Co., Ltd: Company Product and Service Offerings
Table 258. Bora Pharmaceuticals Co., Ltd: Company Financial Strengths Analysis 2019 (US$ Million)
Table 259. Bora Pharmaceuticals Co., Ltd: Company Growth Share Analysis 2019 (%)
Table 260. Bora Pharmaceuticals Co., Ltd: Company Recent Developments till Jan, 2021
Table 261. Bora Pharmaceuticals Co., Ltd: Company Recent Developments till Jan, 2021
Table 262. IRIDEX Corporation: Company Information
Table 263. IRIDEX Corporation: Company Product and Service Offerings
Table 264. IRIDEX Corporation: Company Financial Strengths Analysis 2019 (US$ Million)
Table 265. IRIDEX Corporation: Company Growth Share Analysis 2019 (%)
Table 266. IRIDEX Corporation: Company Recent Developments till Jan, 2021
Table 267. IRIDEX Corporation: Company Recent Developments till Jan, 2021
Table 268. Eyepoint Pharmaceuticals, Inc: Company Information
Table 269. Eyepoint Pharmaceuticals, Inc: Company Product and Service Offerings
Table 270. Eyepoint Pharmaceuticals, Inc: Company Financial Strengths Analysis 2019 (US$ Million)
Table 271. Eyepoint Pharmaceuticals, Inc: Company Growth Share Analysis 2019 (%)
Table 272. Eyepoint Pharmaceuticals, Inc: Company Recent Developments till Jan, 2021
Table 273. Eyepoint Pharmaceuticals, Inc: Company Recent Developments till Jan, 2021
Table 274. KalVista Pharmaceuticals, Inc: Company Information
Table 275. KalVista Pharmaceuticals, Inc: Company Product Pipeline
Table 276. KalVista Pharmaceuticals, Inc: Company Financial Strengths Analysis 2019 (US$ Million)
Table 277. KalVista Pharmaceuticals, Inc: Company Growth Share Analysis 2019 (%)
Table 278. KalVista Pharmaceuticals, Inc: Company Growth Share Analysis 2019 (%)
Table 279. Ellex Medical Lasers Limited: Company Information
Table 280. Ellex Medical Lasers Limited: Company Product and Service Offerings
Table 281. Ellex Medical Lasers Limited: Company Financial Strengths Analysis 2019 (US$ Million)
Table 282. Ellex Medical Lasers Limited: Company Growth Share Analysis 2019 (%)
Table 283. Ellex Medical Lasers Limited: Company Growth Share Analysis 2019 (%)
Table 284. ThromboGenics NV: Company Information
Table 285. ThromboGenics NV: Company Product and Service Offerings
Table 286. ThromboGenics NV: Company Product Pipeline
Table 287. ThromboGenics NV: Company Financial Strengths Analysis 2019 (US$ Million)
Table 288. ThromboGenics NV: Company Growth Share Analysis 2019 (%)
Table 289. ThromboGenics NV: Company Growth Share Analysis 2019 (%)
Table 290. EyeGate Pharmaceuticals, Inc: Company Information
Table 291. EyeGate Pharmaceuticals, Inc: Company Product Pipeline
Table 292. EyeGate Pharmaceuticals, Inc: Company Financial Strengths Analysis 2019 (US$ Million)
Table 293. EyeGate Pharmaceuticals, Inc: Company Growth Share Analysis 2019 (%)
Table 294. EyeGate Pharmaceuticals, Inc: Company Growth Share Analysis 2019 (%)
Table 295. Ophthalix, Inc: Company Information
Table 296. Ophthalix, Inc: Company Product and Service Offerings
Table 297. Ophthalix, Inc: Company Financial Strengths Analysis 2019 (US$ Million)
Table 298. Ophthalix, Inc: Company Growth Share Analysis 2019 (%)
Table 299. Ophthalix, Inc: Company Recent Developments till Jan, 2021
Table 300. Ophthalix, Inc: Company Recent Developments till Jan, 2021
Table 301. GenSight Biologics SA: Company Information
Table 302. GenSight Biologics SA: Company Product and Service Offerings
Table 303. GenSight Biologics SA: Company Product Pipeline
Table 304. GenSight Biologics SA: Company Financial Strengths Analysis 2019 (US$ Million)
Table 305. GenSight Biologics SA: Company Growth Share Analysis 2019 (%)
Table 306. GenSight Biologics SA: Company Recent Developments till Jan, 2021
Table 307. GenSight Biologics SA: Company Recent Developments till Jan, 2021
Table 308. Neurotech Pharmaceuticals, Inc.: Company Information
Table 309. Neurotech Pharmaceuticals, Inc.: Company Product and Service Offerings
Table 310. Neurotech Pharmaceuticals, Inc.: Company Product Pipeline
Table 311. Neurotech Pharmaceuticals, Inc.: Company Product Pipeline
Table 312. Phio Pharmaceuticals: Company Information
Table 313. Phio Pharmaceuticals: Company Product Pipeline
Table 314. Phio Pharmaceuticals: Company Financial Strengths Analysis 2019 (US$ Million)
Table 315. Phio Pharmaceuticals: Company Growth Share Analysis 2019 (%)
Table 316. Phio Pharmaceuticals: Company Recent Developments till Jan, 2021
Table 317. Phio Pharmaceuticals: Company Recent Developments till Jan, 2021
Table 318. Kubota Pharmaceutical Holdings Co., Ltd: Company Information
Table 319. Kubota Pharmaceutical Holdings Co., Ltd: Company Product Pipeline
Table 320. Kubota Pharmaceutical Holdings Co., Ltd: Company Financial Strengths Analysis 2019 (US$ Million)
Table 321. Kubota Pharmaceutical Holdings Co., Ltd: Company Growth Share Analysis 2019 (%)
Table 322. Kubota Pharmaceutical Holdings Co., Ltd: Company Recent Developments till Jan, 2021
Table 323. Kubota Pharmaceutical Holdings Co., Ltd: Company Recent Developments till Jan, 2021
Table 324. Aerpio Pharmaceuticals, Inc.: Company Information
Table 325. Aerpio Pharmaceuticals, Inc.: Company Product and Service Offerings
Table 326. Aerpio Pharmaceuticals, Inc.: Company Product Pipeline
Table 327. Aerpio Pharmaceuticals, Inc.: Company Financial Strengths Analysis 2019 (US$ Million)
Table 328. Aerpio Pharmaceuticals, Inc.: Company Growth Share Analysis 2019 (%)
Table 329. Aerpio Pharmaceuticals, Inc.: Company Recent Developments till Jan, 2021
Table 330. Aerpio Pharmaceuticals, Inc.: Company Recent Developments till Jan, 2021
Table 331. Ampio Pharmaceuticals, Inc: Company Information
Table 332. Ampio Pharmaceuticals, Inc: Company Product Pipeline
Table 333. Ampio Pharmaceuticals, Inc: Company Financial Strengths Analysis 2019 (US$ Million)
Table 334. Ampio Pharmaceuticals, Inc: Company Growth Share Analysis 2019 (%)
Table 335. Ampio Pharmaceuticals, Inc: Company Recent Developments till Jan, 2021
Table 336. Ampio Pharmaceuticals, Inc: Company Recent Developments till Jan, 2021
Table 337. Kodiak Sciences Inc: Company Information
Table 338. Kodiak Sciences Inc: Company Product Pipeline
Table 339. Kodiak Sciences Inc: Company Financial Strengths Analysis 2019 (US$ Million)
Table 340. Kodiak Sciences Inc: Company Growth Share Analysis 2019 (%)
Table 341. Kodiak Sciences Inc: Company Recent Developments till Jan, 2021
Table 342. Kodiak Sciences Inc: Company Recent Developments till Jan, 2021
Table 343. Opsis Therapeutics: Company Information
Table 344. Opsis Therapeutics: Company Product and Service Offerings
Table 345. Opsis Therapeutics: Company Product and Service Offerings
Table 346. Grevis Pharmaceutical: Company Information
Table 347. Grevis Pharmaceutical: Company Product and Service Offerings
Table 348. Grevis Pharmaceutical: Company Product and Service Offerings
Table 349. The Innovexia Life Sciences: Company Information
Table 350. The Innovexia Life Sciences: Company Product and Service Offerings
Table 351. The Innovexia Life Sciences: Company Product and Service Offerings

List of Figures
Figure 1. Structure Of The Eye
Figure 2. AMD Addressable Patient Population (Numbers)
Figure 3. Physiological Changes In Wet And Dry AMD
Figure 4. Glaucoma Addressable Patient Population (Numbers)
Figure 5. Schematic Of Open And Closed Angle Glaucoma
Figure 6. Dry Eye Syndrome Addressable Patient Population (Numbers)
Figure 7. UVEITIS Addressable Patient Population (Numbers)
Figure 8. Prominent Factors Affecting Growth of Ophthalmic Drug Manufacturer Market
Figure 9. Market Drivers for Growth of Ophthalmic Drug Manufacturer Market
Figure 10. Opportunities in the Global Ophthalmic Drug Manufacturer Market
Figure 11. Growth Restrains in the Global Ophthalmic Drug Manufacturer Market
Figure 12. SWOT Analysis of Ophthalmic Drug Manufacturer Market
Figure 13. Porter’s Five Forces Analysis of Ophthalmic Drug Manufacturer Market
Figure 14. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
Figure 15. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
Figure 16. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
Figure 17. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
Figure 18. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
Figure 19. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
Figure 20. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
Figure 21. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
Figure 22. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
Figure 23. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
Figure 24. Johnson & Johnson Vision: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 25. Johnson & Johnson Vision: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 26. Johnson & Johnson Vision: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 27. F. Hoffmann-La Roche AG: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 28. F. Hoffmann-La Roche AG: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 29. F. Hoffmann-La Roche AG: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 30. Pfizer Pharmaceutical: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 31. Pfizer Pharmaceutical: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 32. Pfizer Pharmaceutical: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 33. Novartis AG: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 34. Novartis AG: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 35. Novartis AG: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 36. Merck & Co., Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 37. Merck & Co., Inc: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 38. Merck & Co., Inc: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 39. AbbVie Inc.: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 40. AbbVie Inc.: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 41. AbbVie Inc.: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 42. Takeda Pharmaceutical: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 43. Takeda Pharmaceutical: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 44. Takeda Pharmaceutical: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 45. Essilor International Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 46. Essilor International Company: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 47. Essilor International Company: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 48. Teva Pharmaceutical: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 49. Otsuka Holdings Co., Ltd: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 50. Bausch Health Companies Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 51. Bausch Health Companies Inc: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 52. Bausch Health Companies Inc: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 53. Alcon Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 54. Regeneron Pharmaceuticals, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 55. Recipharm publ AB: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 56. Beximco Pharmaceuticals Limited: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 57. Edwards Lifesciences: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 58. Edwards Lifesciences: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 59. Edwards Lifesciences: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 60. Cooper Companies, Inc.: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 61. Cooper Companies, Inc.: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 62. Cooper Companies, Inc.: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 63. Santen Pharmaceutical Co., Ltd: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 64. Santen Pharmaceuticals: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 65. Rohto Pharmaceutical: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 66. Rohto Pharmaceutical: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 67. Rohto Pharmaceutical: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 68. Carl Zeiss Meditec AG: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 69. Carl Zeiss Meditec AG: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 70. Carl Zeiss Meditec AG: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 71. Topcon Corporation: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 72. Veeva Systems Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 73. Menicon Co., Ltd: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 74. Chengdu Kanghong Pharmaceutical Group Co., Ltd: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 75. Glaukos Corporation: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 76. STAAR Surgical: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 77. Omeros Corporation: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 78. Aerie Pharmaceuticals, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 79. Hoya Corporation: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 80. Alimera Sciences, Inc.: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 81. Alimera Sciences, Inc.: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 82. Bora Pharmaceuticals Co., Ltd: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 83. IRIDEX Corporation: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 84. IRIDEX Corporation: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 85. IRIDEX Corporation: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 86. Eyepoint Pharmaceuticals, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 87. KalVista Pharmaceuticals, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 88. Ellex Medical Lasers Limited: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 89. Ellex Medical Lasers Limited: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 90. Ellex Medical Lasers Limited: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 91. ThromboGenics NV: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 92. EyeGate Pharmaceuticals, Inc: Company Revenue 2015-2019 (US$Mn, AGR %) Figure 93. Ophthalix, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 94. GenSight Biologics SA: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 95. Phio Pharmaceuticals: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 96. Kubota Pharmaceutical Holdings Co., Ltd: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 97. Aerpio Pharmaceuticals, Inc.: Company Revenue 2015-2019 (US$Mn, AGR %)